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A proteomic time course through 
the differentiation of human 
induced pluripotent stem cells into 
hepatocyte-like cells
Tracey Hurrell1,5, Charis-Patricia segeritz2,3, Ludovic Vallier2,3,4, Kathryn S. Lilley4,5 & 
Allan D. Cromarty  1
Numerous in vitro models endeavour to mimic the characteristics of primary human hepatocytes 
for applications in regenerative medicine and pharmaceutical science. Mature hepatocyte-like cells 
(HLCs) derived from human induced pluripotent stem cells (hiPSCs) are one such in vitro model. Due 
to insufficiencies in transcriptome to proteome correlation, characterising the proteome of HLCs is 
essential to provide a suitable framework for their continual optimization. Here we interrogated the 
proteome during stepwise differentiation of hiPSCs into HLCs over 40 days. Whole cell protein lysates 
were collected and analysed using stabled isotope labelled mass spectrometry based proteomics. 
Quantitative proteomics identified over 6,000 proteins in duplicate multiplexed labelling experiments 
across two different time course series. Inductive cues in differentiation promoted sequential 
acquisition of hepatocyte specific markers. Analysis of proteins classically assigned as hepatic markers 
demonstrated trends towards maximum relative abundance between differentiation day 30 and 32. 
Characterisation of abundant proteins in whole cells provided evidence of the time dependent transition 
towards proteins corresponding with the functional repertoire of the liver. This data highlights how 
far the proteome of undifferentiated precursors have progressed to acquire a hepatic phenotype and 
constructs a platform for optimisation and improved maturation of HLC differentiation.
The liver performs many metabolic processes including the detoxification of endogenous and xenobiotic com-
pounds, which makes it a major contributor to high drug attrition rates1. Beyond the liver’s cellular diversity, 
intricate biophysical and biochemical cues, extracellular matrix, and local distribution of secreted factors contrib-
ute to the complexity of the liver2. Freshly isolated primary human hepatocytes (PHH) remain the “gold stand-
ard” for functional hepatocytes as liver-specific gene expression deteriorates with cryopreservation or plating3,4. 
However, improvements in the utilization of primary cells have negated some of these concerns5–7. Due to the 
historical limitations of PHHs, hepatocytes models have been developed to meet the challenges of logistics, prac-
ticality, complexity, reliability, reproducibility, and biological context of the liver in vitro8. Induced pluripotent 
stem cells (iPSCs) have revolutionized developmental biology and provide a source of self-renewing cells for in 
vitro models9–11.  Embryonic development is highly co-ordinated and provides a guideline for in vitro hepatocyte 
differentiation which can be mimicked using a multistage differentiation cascade through endoderm, anterior 
definitive endoderm, hepatocyte commitment, and hepatocyte maturation12–14. Differentiation to hepatocyte-like 
cells (HLC) begins with endoderm induction which typically makes use of a standard combination of growth 
factors. However, variation in the specification, extracellular matrices, culture format, and duration of culture 
influence differentiation kinetics14–21. Transcripts, protein expression, and functional activity of differentiated 
HLCs reportedly reflect a foetal phenotype22,23. Such limitations in differentiation are being addressed by 3D 
culture techniques in scalable technologies using spheroids24 and liver-on-a-chip25 approaches. However, in order 
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for HLCs to be used as a surrogate for mature hepatocytes, robust phenotypic and functional characterisation is 
continually required. Despite specific mRNAs clusters suggested to define the hepatic phenotypic13,17, the changes 
in the proteome during differentiation are less rigorously investigated compared to the transcriptome. This study 
provides two proteomic time courses through HLC differentiation and illustrates the ability to trace hepatic 
marker proteins throughout in vitro differentiation. Isobaric tagging (TMT/iTRAQ) was employed, which allows 
for direct ratiometric comparison of independently collected samples and enables the relative quantification of 
large numbers of abundant proteins26. Using this quantitative proteomics approach, the lengths to which HLCs 
have progressed from undifferentiated precursors and the time dependent changes in relative abundance of pro-
teins corresponding to the functional repertoire of hepatocytes was demonstrated.
Results
Differentiation of hepatocyte-like cells. Differentiation was observed morphologically (Fig. 1) as hiP-
SCs transition to anterior definitive endoderm which then acquire an epithelial-like morphology characteristic 
of hepatic progenitors, and finally mature to distinctly boundaried HLCs. RNA expression of hepatic markers 
albumin, A1AT, AFP, HNF4α as well as metabolizing enzymes CYP3A5 and CYP3A7 on day 35 of HLC differ-
entiation was compared to hiPSCs and PHH donor samples (Supplementary 2: Fig. S2). Although expression did 
not rival that of PHHs, HLCs had increased mRNA expression compared to hiPSCs which was considered suffi-
ciently representative of a transition to hepatic progenitors. Samples throughout six independent differentiations 
were harvested for various proteomic time courses.
Overview of protein expression and principal component analysis. Relative quantification of pro-
teins was determined across independent biological replicates with each replicate undergoing 30 hours of mass 
spectrometry to generate the protein cohorts described. Replicates 1 and 2 of the complete differentiation time 
course (HLCTC) from day 1 to day 35, identified 6,789 and 6,980 proteins respectively (Supplementary 1: Default 
report HLCTC replicate 1 and replicate 2). Filtering for protein group(s) with two or more unique peptides and 
a 100% confidence constrained the dataset to 5,727 proteins (Fig. 2a and Supplementary 1: HLCTC Replicate 
overlap). Within the maturation time course (HLCLTC) from day 16 to day 40, identified 6,695 and 6,255 pro-
teins were in replicates 1 and 2 respectively (Supplementary 1: Default report HLCLTC replicate 1 and replicate 
Figure 1. Phase contrast images of cell morphology through differentiation (EVOS FL Cell Imaging System, 
scale bar: 1000 µm). (a) Human iPSCs (not at differentiation density), (b) Anterior definitive endoderm at 
day 6, (c) Hepatic endoderm at day 9, (d) Hepatocyte-like cell maturation at day 16, (e) Hepatocyte-like cell 
maturation at day 25, and (f) HLCs at day 35.
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2) which constrained to 5,598 proteins when filtered (Fig. 2d and Supplementary 1: HLTLTC Replicate overlap). 
Principal component analysis (PCA) was done to reduce the redundancy of related data properties and sum-
marize the data using the best linear combinations. These plots (Fig. 2b and c) achieved grouping of endoderm 
specification and commitment (day 1 and day 3) compared to anterior definitive endoderm specification and 
hepatocyte maturation (day 5, day 7, and day 10). Hepatocyte maturation (day 25, day 30, and day 35) was clearly 
segregated from the early time points in Component 1. PCA Component 1, which accounted for 50.3% of the 
variance, was able to distinguish HLCs from their undifferentiated precursors. Components 2 and 3 were able 
to distinguish the transition from iPSCs into endoderm. The lack of homogeneity in Components 2 and 3 at day 
25, 30, and 35 could be due to the concomitant existence of other cell types during differentiation as HLCs were 
not specifically isolated from the total cellular cohort prior to analysis. However, under optimal conditions this 
differentiation protocol produces HLCs with more than 85% co-expression of albumin and A1AT from day 2027. 
In the maturation time course Component 1 made up 60.6% of the variance with the main distinction being to 
separate day 40 from the rest of the time points (Fig. 2e and f). While technical replicates of mass spectrometry 
can impact proteome coverage, this was not conducted as the protein identification was robust with the results of 
hierarchical clustering and PCA being able to demonstrate biological significance and not technical features of 
the labelled proteomics approach.
Hierarchical clustering and hepatic markers throughout differentiation. Hierarchical clustering 
of samples across the complete differentiation time course generally co-segregated according to the differenti-
ation phase with the major nodes distinguishing samples from day 1 to 10, and day 25 to 35 (Fig. 3a). Protein 
profiles highlighted similarities across a large proportion of the proteome but produced protein cohorts which 
increased or decreased over time (Fig. 3b). This provided proteins to scrutinize for insight into differentiation 
(Supplementary 1: HLCTC Hierarchical clustering and HLCTC generic clustering).
Schwartz et al. summarised the expected expression patterns throughout the differentiation cascade which 
distinguishes various cellular phenotypes (Supplementary 2: Table S2). Theses, in addition to proteins described 
by others provided the basis for hepatocyte characterisation12–14,17,21,22,28,29. Proteins governing transitions from 
pluripotency (NANOG, OCT4, SOX2 and SSEA3/4) were not detected, which could be expected as no nuclear 
enrichment was employed during protein extraction from whole cells. Despite lacking characteristic pluripotency 
markers, abundant proteins in hiPSCs included proteins associated with multicellular organismal development 
(lymphoid-specific helicase), G2/M transition (telomeric repeat-binding factor 1) and spindle-assembly check-
point signalling. SOX17 modulates differentiation via WNT3A, which governs the development of regionalized 
endoderm, and was most abundant at day 5 suggestive of the transition into definitive endoderm. Additionally, 
neural cell adhesion molecule-1 (NCAM1), which is responsible for the organogenesis of mesodermal and endo-
dermal derivatives, was the most abundant during foregut endoderm formation. Hepatic endoderm samples were 
rich in proteins involved in multicellular organismal development such as protein shisa-2 and vang-like protein 
1 homolog.
Figure 2. Overview of protein expression and PCA of the complete differentiation time course (HLCTC) 
and maturation time course (HLCLTC). (a) Number of proteins quantified per replicated in HLCTC with the 
corresponding overlap in commonly quantified proteins, (b) PCA comparing Component 1 and 2 during the 
HLCTC, (c) PCA comparing Component 1 and 3 during the HLCTC, (d) Number of proteins quantified per 
replicated in HLCLTC with the corresponding overlap in commonly quantified proteins, (e) PCA comparing 
Component 1 and 2 during the HLCLTC, and (f) PCA comparing Component 1 and 3 during the HLCLTC.
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Subsets of the clustered proteins (Cluster 5710 with 96 proteins, Cluster 5691 with 21 proteins, and Cluster 
5709 with 56 proteins) which accounted for the most dynamic variance were extracted and hierarchical clustering 
was re-performed. This clustered day 35 closer to less differentiated precursors than samples from day 25 and 
day 30 (Fig. 4a and Supplementary 1: HLCTC reduced matrix). Proteins marking a hepatocyte phenotype were 
consistently identified across replicates and displayed the greatest abundance on differentiation day 30 (Fig. 4b).
Differentiation of hiPSCs to HLCs requires the conversion from cell proliferation and migration to matu-
ration. Quantification of selected proteins associated with cell growth was compared (Fig. 4c). Ki-67, a protein 
responsible for maintaining cell proliferation, was reduced in abundance from day 1 to 5 after which expression 
appeared stable. Proteins associated with cell cycle progression, which decreased throughout differentiation, 
included cyclin-dependent kinase-1, cyclin-dependent kinase 4, Geminin, and M-phase inducer phosphatase-3. 
The opposite was observed for cyclin-dependent kinase inhibitor 1B (CDKN1B, P46527) which governs G1 arrest 
by inhibiting cyclin E- and cyclin A-CDK2 complexes. These abundance changes demonstrated a reduction in 
proliferation during differentiation.
Hierarchical clustering and markers throughout maturation. Hierarchical clustering for the mat-
uration time course did not co-segregate chronologically (Fig. 5a and Supplementary 1: HLCLTC Hierarchical 
clustering) with day 24 and day 40 forming separate nodes. This could be a result of having only a single replicate 
for these two data points. However in PCA, HLCs on differentiation day 24 clustered well with samples from day 
16 to day 36, which was not apparent for HLCs at day 40. During maturation, the characteristic hepatic markers 
investigated generally had greater abundance at day 28 and 32 (Fig. 5b). Here, as was evident in the complete 
differentiation time course, most phase I metabolizing enzymes were absent with none of the major CYP450 iso-
forms (CYP1A2, CYP3A4, CYP3A5, CYP2B6, CYP2C9, CYP2C19, and CYP2D6) identified confidently. Despite 
smaller fold-change differences in hepatic markers, some of which did not meet a distinct statistical cut-off, the 
two time course series were highly complementary. Reduced intensity differences could be as a result of the ratios 
Figure 3. Hierarchical clustering and protein profiling throughout HLC differentiation. (a) Hierarchical 
clustering through HLC differentiation and (b) Clusters with profiles of proteins which have similar abundance 
changes over time.
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being compared to already differentiated cells which have transitioned to early HLCs as opposed to the compar-
ison relative to hiPSCs.
Functional protein association networks. Hepatic lineages mature and acquire metabolic properties 
under a network of six functionally cross-regulating transcription factors with HNF4α controlling hepatic gene 
expression30. In addition, inductive cues promote sequential acquisition of nuclear transcription factor HNF4α in 
hepatic progenitors, AFP in hepatoblasts and albumin in hepatocytes13. This sequential acquisition, although not 
identical to in vitro differentiation, was used to select query proteins for assessing functional protein association 
networks.
The STRING database (http://string-db.org) was used to assess protein–protein interactions in functional 
protein association networks using core factors as query proteins. hiPSCs and anterior definitive endoderm query 
proteins were SOX2 and FOXA2 (Supplementary 2: Fig. S3). Despite a limited number of interactors being pres-
ent, quantified protein interactors had higher abundance in hiPSCs. Proteins emerging during hepatic endo-
derm differentiation, APOA1 and APOB, had approximately half of the queried interactors quantified. A two-fold 
increase in expression of queried proteins APOA1, APOB, and interactors FGA and TTR were evident by day 10 
which increased to a maximum around day 25 to 30.
Figure 4. Hierarchical clustering of protein subsets from HLC differentiation. (a) Hierarchical clustering of 
Clusters 5710, 5691, and 5709 which accounted for the majority of variance throughout the time course, (b) 
Expression profiles of proteins marking a hepatic phenotype, and (c) Expression profiles of proteins marking 
proliferation alongside cyclin-dependent kinase inhibitor 1B (CDKI1B) which is involved in G1 arrest.
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Albumin, AFP and TTR were used as query proteins for hepatoblasts, which also had approximately half of 
the queried interactors quantified. While not demonstrating large fold-change differences across these proteins 
between day 25 and 35 of differentiation, the expression of hepatic proteins as well as key interactors demon-
strates the progression through differentiation. HLCs had the most functional protein network interactors quan-
tified (Supplementary 2: Fig. S4) while the relative abundance was maximally observed on day 28 or day 32. 
This query approach enabled extraction of quantitation information associated with key regulators which appear 
throughout differentiation.
Discussion
Previously we have compared the proteome of the HLCs differentiated to day 35, under the same conditions char-
acterized here, to other hepatic cell types31. While better correlated to PHHs than HepG2 monolayers or HepG2 
3D spheroids, the phenotype of HLCs does not rival that of PHH donors. However, as no single hepatic model has 
yet been shown capable to mimic all in vivo hepatic functions, tracing the transitions of iPSCs into hepatic pro-
genitors and further functionally qualifying HLCs provides an additional avenue for improving existing hepatic 
phenotypes. Functional characterisation and transcriptome analysis may not be sufficient for these qualifications 
making proteomic analysis such as these essential.
Although the correlation is not absolute, the coordinated pattern of embryonic liver development provides 
a guideline for in vitro hepatocyte differentiation. The liver develops following endodermal patterning via the 
ventral wall of the foregut endoderm, with differentiation of hepatoblasts into hepatic lineages and maturation 
completing developmental progression30. The ability of hierarchical clustering to sequentially segregate samples 
suggests a coordinated developmental pattern is successfully transitioning the proteome from undifferentiated 
precursors. The inability to segregate the maturation time course very specifically by collection time points 
could be as a result of reduced fold change differences in proteins once already expressing an HLC phenotype. 
Figure 5. Hierarchical clustering of all proteins and hepatic marker subsets throughout HLC maturation.  
(a) Hierarchical clustering through HLC maturation and (b) Expression profiles of proteins marking a hepatic 
phenotype.
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In addition, the detection of lower abundance and hydrophobic proteins such as those required for metabolism, 
which are more likely to distinguish maturation, was likely limited by whole cell analysis.
Proteins used as markers for hepatocyte phenotypes were most abundant around day 30 of differentiation 
for the complete time course. If these proteins are accurate markers of hepatocytes, whether of an adult or foetal 
phenotype, then differentiating beyond 30 days may have a reduced hepatocyte-specific proteome explaining 
the clustering of day 35 with less differentiated counterparts. This phenomenon could not be inferred from a 
singular overview of the differentiation series which necessitated a similar comparison incorporating alterna-
tive time points. During maturation, hepatic markers were highly complementary to the differentiation time 
course and generally had the greatest abundance at day 28 and 32. Variance in the relative ratio of some proteins, 
despite undergoing adequate normalisation, points to concurrent and subsequent differentiations not always 
being tightly regulated. In spite of this, independently differentiated biological replicates of separate time courses 
suggests that maintaining the HLC proteome has definitive limits, which was previously demonstrated as a feature 
of this differentiation protocol27.
Correlation of the transcriptional fingerprint of differentiation from hiPSCs was not directly investigated 
here. However, there are 40 mRNAs suggested to be expressed solely in the liver when derived from hiPSCs17. 
Numerous proteins corresponding to this transcriptional fingerprint were identified. Serine-pyruvate ami-
notransferase, haptoglobin, s-adenosylmethionine synthase isoform type-1, prothrombin, angiotensinogen, 
heparin cofactor 2, and alpha-2-HS-glycoprotein were elevated at day 30 in the complete differentiation time 
course. Additionally, complement factor B, antithrombin-III, protein AMBP, complement 5, ribonuclease 4, 
beta-2-glycoprotein 1, fibrinogen alpha chain, vitronectin, fibrinogen gamma chain, and apolipoprotein A-II 
were also identified during maturation. Evidence of these correlations can be considered valuable support for this 
differentiation protocol.
hiPSCs differentiated using various strategies report numerous hepatocyte characteristics while the expression 
of mRNAs encoding phase I and phase II enzymes is largely incomplete17. Here there was a noteworthy absence of 
the major hepatic metabolizing enzymes, which is a potential limitation as six CYP450 enzyme isoforms collec-
tively account for approximately 95% of CYP450-mediated reactions32,33. While limited in their expression of the 
panel of phase I and phase II metabolising enzymes raises some concerns over the phenotype of HLCs it cannot 
be established whether this was mostly due to limited protein abundance or as a result of the loss of hydropho-
bic peptides during  proteomics sample preparation and analysis. Therefore, targeted proteomic investigation is 
required to further identify the extent of expression of the repertoire of metabolising enzymes.
An important characteristic essential to mimicking hepatocytes in vivo is the non-replicating state of PHHs, 
which is not achieved in immortalized cell lines. However, differentiation of hiPSCs to HLCs using this differen-
tiation protocol demonstrated that cells undergo the conversion from proliferation and migration to maturation. 
Decreases in cell cycle regulating proteins, combined with the progressive increase in abundance of many hepatic 
proteins from hiPSC to HLCs, illustrates successful augmentation of the proteome.
Conclusion
Mature HLCs are a valuable resource in regenerative medicine and pharmaceutical sciences. To the extent of our 
knowledge, there is no published data which has as comprehensively and systematically examined the proteome 
during differentiation of hiPSCs into HLCs. This proteomic data can be used as a resource for correlating in vitro 
differentiation with in vivo liver development and constructs a platform for optimisation of differentiation and 
the acquisition of mature HLCs. While limited in detection of low abundant proteins, protein localizations, and 
protein isoforms, this data provided the identification of thousands of proteins and created a proteomic reference 
platform through the transitions from pluripotency to HLCs. Despite the stochastic nature and variability of the 
proteome and differentiation, hepatic markers reproducibly demonstrated a trend towards maximum relative 
abundance between differentiation day 30 and 32. Characterisation of abundant proteins in whole cells provided 
evidence of time-dependent transition towards proteins corresponding with the functional repertoire of the liver 
and highlights the lengths to which HLCs have progressed from undifferentiated precursors.
Materials and Methods
Cell culture and differentiation. Human induced pluripotent stem cells (hiPSCs) were generated as 
previously reported11,27,34, where the chronological gene expression patterns through differentiation have been 
described. Prior to differentiation, hiPSCs were cultured in chemically-defined medium with polyvinyl alcohol 
(CDM-PVA: 250 ml Iscove’s Modified Dulbecco’s Media, 250 ml Ham’s F12 + GlutaMAX, 1% concentrated lipids, 
0.7% insulin, 0.14% transferrin, 0.1% PVA, 1% penicillin/streptomycin supplemented with 10 ng/ml Activin A 
and 12 ng/ml FGF-2) and maintained in a tri-gas incubator (5% O2, 5% CO2, 90% N2) at 37 °C. Differentiation, 
using hiPSCs within 3–10 passages of thawing, was conducted as previously reported27 (Supplementary 2: Fig. S1).
Sample collection. Cells were harvested for two proteomics series; a complete differentiation time course 
(hepatocyte-like cell time course: HLCTC) which included time points at days 1, 3, 5, 7, 10, 25, 30, and 35 from 
two separate differentiations with replicates at days 1, 5, 10, and 30. The second series constituted only days during 
HLC maturation (hepatocyte-like cell late time course: HLCLTC) which included time points at days 16, 20, 24 
28, 32, 36, and 40 from two separate differentiations with replicates at days 16, 20, 28, 32, and 36. Cells were lysed 
using a Tris-based buffer (10 mM Tris-HCL (pH 8), 1 mM ethylenediaminetetraacetic acid, 0.5 mM ethylenegly-
coltetraacetic acid, 1% Triton X-100, 0.1% sodium dodecyl sulphate, 0.1% sodium deoxycholate, 140 mM sodium 
chloride, and cOmplete™ protease inhibitor cocktail) assisted by ultrasonic disruption for 10 minutes at 4 °C.
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Protein digestion and TMT-labelling. Protein concentration was determined using the bicinchoninic 
acid assay with a 1:50 ratio of reagent B (4% copper II sulfate pentahydrate) to reagent A (2% sodium carbonate, 
0.16% sodium tartrate, 0.9% sodium bicarbonate and 1% BCA; pH 11.25). Fifty micrograms of protein was 
reduced with 10 mM dithiothreitol at 37 °C and alkylated with 25 mM iodoacetamide for 2 hours at room tem-
perature. Proteins were precipitated overnight at 4 °C with acetone and resuspended in 100 mM HEPES (pH 
8.5). Samples were digested with 1.25 µg (1:40) sequence-grade modified trypsin for 1 hour at 37 °C. Additional 
trypsin (1:40) was added and digestion continued overnight at 37 °C. Tags were equilibrated to room temperature 
and resuspended in mass spectrometry-grade acetonitrile (41 µl per 0.8 mg tag). Digested peptides were clarified 
for 20 minutes at 16 000 g and labelled using TMT 6-plex reagent (Thermo Fisher Scientific) for 2 hours at room 
temperature under constant agitation (Labelling strategy: Supplementary 2: Table S1). Labelling was quenched 
with 8 µl of 5% hydroxylamine for 1 hour and further quenched overnight at 4 °C with dH2O. Labelled samples 
were combined and reduced to dryness by vacuum centrifugation.
Solid phase extraction and peptide fractionation. Peptides were solubilized in dH2O with 0.1% TFA 
and loaded onto a conditioned SepPak C18 cartridge (100 mg). Desalting was conducted and peptides were 
eluted in 70% acetonitrile with 0.05% acetic acid. Eluents were dried and resuspended in 20 mM ammonium 
formate (pH 10) with 4% acetonitrile. Peptides were loaded via a single partial loop injection, onto a Waters 
ACQUITY UPLC BEH C18 column (130 Å, 2.1 mm × 150 mm, 1.7 µm), and fractionation conducted using a 
Waters ACQUITY system. Peptides were profiled at a flow rate of 0.25 ml/minute using an initial isocratic low 
Figure 6. The experimental workflow from sample collection to analysis. Whole cell lysates were collected 
and 50 µg per sample was reduced, alkylated, and digested with trypsin. Peptides derived from each sample 
were differentially labelled with TMT 6-plex reagent and separated using reverse phase high performance 
liquid chromatography (HPLC). Fifteen pre-fractionated samples were analysed using liquid chromatography 
tandem-mass spectrometry (LC-MS/MS) with a linear gradient over 120 minutes. RAW files were converted 
to MGF with peak picking and threshold count filters. Peak lists were searched against a UniProtKB/Swiss-
Prot human database using SearchGUI version 2.3.1 with X!Tandem, MS-GF+ and Comet search engines. 
Identification and quantification were done using Peptide Shaker version 1.7.3 and Reporter version 0.2.13 
respectively. Data analysis and visualisation was conducted using Perseus software.
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organic phase (mobile phase A: 20 mM ammonium formate, pH 10; mobile phase B: 80% acetonitrile, 20 mM 
ammonium formate, pH 10). This was followed by a 50 minute linear gradient of increasing percentage mobile 
phase B (5-60%). Chromatography was monitored using a diode array detector scanning wavelengths between 
200 and 400 nm. Fractions with peak peptide elution were dried and pooled into 15 samples using 0.1% formic 
acid.
LC-MS/MS analysis. Samples were analysed using a Dionex Ultimate 3000 RSLCnano LC system and 
a Thermo Scientific Q Exactive Hybrid Quadrupole-Orbitrap Mass Spectrometer. Peptides (1–2 µg) were 
loaded onto an Acclaim PepMap 100 C18 pre-column (100 Å, 300 µm × 5 mm, 5 µm) using an Ultimate 3000 
auto-sampler with 0.1% formic acid for 3 minutes at a flow rate of 10 µl/minute prior to elution onto a PepMap 
C18, EASY-Spray LC (100 Å, 75 µm × 500 mm, 2 µm) analytical column. Peptide separation was profiled at 300 nl/
minute by applying a linear gradient of 4–40% using mobile phase A (H2O with 0.1% formic acid) and mobile 
phase B (80% acetonitrile, 20% H2O with 0.1% formic acid) over 100 minutes using a 120 minute run time. Mass 
spectrometry measured the mass-to-charge ratios (m/z) in positive ion data-dependent mode. Full MS scans were 
performed in the range of 380–1500 m/z at a resolution of 70,000 with an automatic gain control (AGC) of 5 × 106 
with a maximum injection time of 250 ms. Data dependent scans of the top 20 most abundant ions, with charge 
states between 2+ and 5+, were automatically isolated, selected and fragmented by higher energy collisional 
dissociation (HCD) in the quadrupole mass analyser. Dynamic exclusion was set at 60 seconds. HCD fragmen-
tation was performed at a normalized collision energy (NCE) of 32.5% and a stepped NCE of 10% at a resolution 
of 17,500. The AGC, maximum injection time, first fixed mass and isolation window for MS2 scans was 5 × 104, 
150 ms, 100 m/z and 1.2 m/z respectively.
Data processing. Raw data files were converted to MGF using ProteoWizard MSConvertGUI35 with filters 
for peak picking and a threshold count of 150. Peak lists were searched against a UniProtKB/Swiss-Prot human 
database (Homo sapiens, Canonical sequence, January 2016, Sequences: 20,194) using SearchGUI version 2.3.136 
with X!Tandem, MS-GF+ and Comet search engines. Post-processing of peptide-spectrum matches (PSM) for 
protein identification was done using Peptide Shaker version 1.7.337. Search parameters included: minimum and 
maximum precursor mass of 300 and 900 Da respectively, precursor mass tolerance of 10 ppm, fragment mass 
tolerance of 0.2 Da and a maximum number of 2 missed cleavages. Fixed modifications included carbamidome-
thyl of cysteine, TMT 6-plex modification of lysine and peptide N-termini with variable modifications including 
oxidation of methionine and deamidation of asparagine or glutamine. Reporter version 0.2.13 (http://compom-
ics.github.io/projects/reporter.html) was employed for deisotoping and relative quantification. PSM level ratios 
were estimated with the use of the median of all non-null intensities and a maximum likelihood estimator used 
for aggregation into peptide and subsequent protein grouping ratios.
Data analysis and visualisation. Proteins present in respective replicates and identified with 100% con-
fidence using a minimum of 2 unique peptides were analysed in Perseus version 1.5.3.1 (Max Planck Institute 
of Biochemistry). Protein profiles were generated and clustering established based on Euclidean distances from 
reference profiles. Protein ratios, using the average across replicates, were expressed relative to controls. K-mean 
pre-processing and average linkages were used for hierarchical clustering. Where applicable, multi-sample testing 
was conducted using ANOVA with a permutation-based false discovery rate (FDR) for truncation, and a FDR of 
0.01 with 250 randomizations. PCA was done using a Benjamini-Hochberg cut-off method with a FDR of 0.01. 
Proteins were annotated for gene ontology (GO) biological processes (BP), molecular functions (MF), cellular 
components (CC) as well as Reactome and KEGG pathway identifiers. Data was interrogated for protein-protein 
interactions using STRING (Search Tool for the Retrieval of Interacting Genes/Proteins). Proteins associated 
with each phase of differentiation were selected and 10 interactors with a 0.900 minimum confidence interaction 
score were assessed for their identification in the data set. The entire experimental workflow is detailed in Fig. 6.
Data Availability
Further details pertaining to protocols, materials and data are available from the corresponding author.
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